| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $384K | — | -70.0% |
| SG&A Expense | $1.5M | — | +45.7% |
| Operating Income | -$1.9M | — | +17.7% |
| Net Income | -$1.8M | — | +19.8% |
| EPS (Basic) | -$0.48 | — | -6.7% |
| EPS (Diluted) | -$0.48 | — | -6.7% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $6.9M | -7.7% | -28.5% |
| Inventory | $93K | — | — |
| Total Assets | $7.5M | -5.1% | -25.4% |
| Total Liabilities | $1.1M | -35.8% | -61.1% |
| Stockholders' Equity | $6.4M | +3.0% | -12.2% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$2.5M | — | -28.2% |
| Financing Cash Flow | $1.9M | — | -77.6% |